Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27615544 | 0.85 | MAPT (0.43) | MAPTALDH1A1LMNAENPP2MEN1 | |
| SCHEMBL14309631 | 0.85 | MAPT (0.51) | MAPTALDH1A1LMNAMETENPP2 | |
| SCHEMBL30481715 | 0.84 | MAPT (0.57) | MAPTALDH1A1LMNAMETENPP2 | |
| SCHEMBL24130446 | 0.84 | MAPT (0.57) | MAPTALDH1A1LMNAMETENPP2 | |
| SCHEMBL6629188 | 0.83 | GPR119 (0.50) | MAPTALDH1A1LMNAMETACHE | |
| SCHEMBL30998112 | 0.83 | MAPT (0.63) | MAPTALDH1A1LMNAMETGPR119 | |
| SCHEMBL4435451 | 0.83 | MAPT (0.63) | MAPTALDH1A1LMNAMETGPR119 | |
| SCHEMBL4718694 | 0.80 | MAPT (0.56) | MAPTALDH1A1LMNAMETACHE | |
| SCHEMBL1247295 | 0.80 | MAPT (0.59) | MAPTALDH1A1LMNAMETENPP2 | |
| SCHEMBL5339319 | 0.80 | HTR1A (0.55) | ALDH1A1ACHEGPR119BACE1TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-1562918-B1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| EP-1562918-B1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-7141562-B2 | Substituted benzoxazinones and uses thereof | ROCHE PALO ALTO LLC (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1562918-A1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004041792-A1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
| US-20040092512-A1 | Substituted benzoxazinones and uses thereof | ROCHE PALO ALTO LLC | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092512-A1 | Substituted benzoxazinones and uses thereof | CYP4X1, CYP3A5, CYP2D6 | MAPT 4743/4885ALDH1A1 389/4885LMNA 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.